XML 31 R19.htm IDEA: XBRL DOCUMENT v3.24.2
GOODWILL AND OTHER INTANGIBLE ASSETS
 6 Months Ended
Jun. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
GOODWILL AND OTHER INTANGIBLE ASSETS GOODWILL AND OTHER INTANGIBLE ASSETS
Goodwill

The changes in the carrying amounts in Goodwill were as follows:
Dollars in millions
Balance at December 31, 2023$21,169 
Acquisitions (Note 4)
580 
Currency translation and other adjustments(17)
Balance at June 30, 2024
$21,732 

Other Intangible Assets

Other intangible assets consisted of the following:

Estimated
Useful Lives		June 30, 2024December 31, 2023
Dollars in millions
Gross carrying amountsAccumulated amortizationOther intangible assets, net Gross carrying amountsAccumulated amortizationOther intangible assets, net
R&D technology(a)
6 years
$1,980 $(110)$1,870 $— $— $— 
Acquired marketed product rights(a)
3 – 15 years
63,473 (44,726)18,747 63,076 (40,184)22,892 
Capitalized software
3 – 10 years
1,532 (1,096)436 1,497 (1,027)470 
IPRD(a)
8,375 — 8,375 3,710 — 3,710 
Total$75,360 $(45,932)$29,428 $68,283 $(41,211)$27,072 
(a)    Includes assets acquired in connection with Mirati and RayzeBio acquisitions, as further described in "—Note 4. Acquisitions, Divestitures, Licensing and Other Arrangements."

Amortization expense of Other intangible assets was $2.4 billion and $4.8 billion during the three and six months ended June 30, 2024 and $2.3 billion and $4.6 billion during the three and six months ended June 30, 2023, respectively.

During the three months ended June 30, 2024, a $280 million impairment charge was recorded in Cost of products sold resulting from lower revised cash flow projections for Inrebic. The charge represented a partial impairment based on the excess of the asset’s carrying value over its estimated fair value using discounted cash flow projections.

Additionally, a $590 million IPRD impairment charge for alnuctamab was recorded in Research and development expense in connection with portfolio prioritization. Alnuctamab was being studied as a potential treatment for hematologic diseases and was obtained in the acquisition of Celgene. The charge represented a full write-down of the asset.
An IPRD impairment charge of $20 million was included in Research and development expenses during the six months ended June 30, 2023.